JP2025508371A5 - - Google Patents

Info

Publication number
JP2025508371A5
JP2025508371A5 JP2024547419A JP2024547419A JP2025508371A5 JP 2025508371 A5 JP2025508371 A5 JP 2025508371A5 JP 2024547419 A JP2024547419 A JP 2024547419A JP 2024547419 A JP2024547419 A JP 2024547419A JP 2025508371 A5 JP2025508371 A5 JP 2025508371A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
sequence shown
domain
acid according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062428 external-priority patent/WO2023154890A2/en
Publication of JP2025508371A publication Critical patent/JP2025508371A/ja
Publication of JP2025508371A5 publication Critical patent/JP2025508371A5/ja
Pending legal-status Critical Current

Links

JP2024547419A 2022-02-11 2023-02-10 Steap1に結合するキメラ抗原受容体 Pending JP2025508371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309389P 2022-02-11 2022-02-11
US63/309,389 2022-02-11
PCT/US2023/062428 WO2023154890A2 (en) 2022-02-11 2023-02-10 Chimeric antigen receptors binding steap1

Publications (2)

Publication Number Publication Date
JP2025508371A JP2025508371A (ja) 2025-03-26
JP2025508371A5 true JP2025508371A5 (cg-RX-API-DMAC10.html) 2026-02-10

Family

ID=87565154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547419A Pending JP2025508371A (ja) 2022-02-11 2023-02-10 Steap1に結合するキメラ抗原受容体

Country Status (4)

Country Link
US (1) US20250144139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4476267A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025508371A (cg-RX-API-DMAC10.html)
WO (1) WO2023154890A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024274301A1 (en) * 2023-05-16 2025-12-11 Fred Hutchinson Cancer Center Pro-inflammatory cytokine enhanced steap1 recombinant receptors
CN119113151B (zh) * 2024-08-01 2025-11-18 华中科技大学同济医学院附属同济医院 一种前列腺癌特异性细胞外囊泡荧光探针及其制备方法
CN121449740A (zh) * 2024-08-01 2026-02-03 南京蓬勃生物科技有限公司 一种结合steap1的抗体或其抗原结合部分及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2845866T (pt) * 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
JP5956342B2 (ja) * 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
WO2014165818A2 (en) * 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3227323B1 (en) * 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
MX2018001568A (es) * 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
JP7085990B2 (ja) * 2015-10-13 2022-06-17 シティ・オブ・ホープ クロロトキシンドメインを含むキメラ抗原レセプター
GB201518136D0 (en) * 2015-10-14 2015-11-25 Glaxosmithkline Ip Dev Ltd Novel chimeric antigen receptors
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
US20210145882A1 (en) * 2018-04-13 2021-05-20 Fred Hutchinson Cancer Research Center Methods for adoptive cell therapy targeting ror1
AU2019275479B2 (en) * 2018-05-21 2022-12-08 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors with modified linker domains and uses thereof
WO2019246593A2 (en) * 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
MX2021000617A (es) * 2018-07-18 2021-04-13 Amgen Inc Receptores quimericos de steap1 y metodos de uso de los mismos.
EA202192103A1 (ru) * 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
CA3130671A1 (en) * 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas Systems Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
GB202208119D0 (en) * 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car

Similar Documents

Publication Publication Date Title
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP2019150066A5 (cg-RX-API-DMAC10.html)
JP2023059873A5 (cg-RX-API-DMAC10.html)
CN102906112B (zh) Trail r2-特异性多聚体支架
JP2024532485A5 (cg-RX-API-DMAC10.html)
US8669350B2 (en) TNF receptor Fc fusion proteins and in vivo methods of use
US20220249563A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP2020532969A5 (cg-RX-API-DMAC10.html)
JP2020108398A5 (cg-RX-API-DMAC10.html)
JP2020512005A5 (cg-RX-API-DMAC10.html)
JP2022537658A5 (cg-RX-API-DMAC10.html)
JP2023513157A5 (cg-RX-API-DMAC10.html)
AU2017345791B2 (en) Multimeric IL-15-based molecules
JP2018512145A5 (cg-RX-API-DMAC10.html)
JP2019528683A (ja) 多量体gitr結合分子及びその使用
JP2021512614A5 (cg-RX-API-DMAC10.html)
JP2015527070A5 (cg-RX-API-DMAC10.html)
JP2019528077A5 (cg-RX-API-DMAC10.html)
JP2019525771A5 (cg-RX-API-DMAC10.html)
JP2021526844A5 (cg-RX-API-DMAC10.html)
JP2018523484A5 (cg-RX-API-DMAC10.html)
JP2014158485A5 (cg-RX-API-DMAC10.html)
JP2019533675A5 (cg-RX-API-DMAC10.html)
JP2023512452A5 (cg-RX-API-DMAC10.html)
Arndt et al. Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting system